Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
Top Cited Papers
- 15 August 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (16), 3150-3157
- https://doi.org/10.1200/jco.2003.04.105
Abstract
Purpose: To assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to solid tumors other than breast or prostate cancer.This publication has 13 references indexed in Scilit:
- The New Bisphosphonate, Zometa®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to PamidronateCancer Investigation, 2002
- Methodology for treatment evaluation in patients with cancer metastatic to bone.JNCI Journal of the National Cancer Institute, 2001
- Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer, 2001
- Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical TrialsJournal of Clinical Oncology, 2001
- Survival analysis for recurrent event data: an application to childhood infectious diseasesStatistics in Medicine, 2000
- Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.Journal of Clinical Oncology, 1998
- Skeletal complications of malignancyCancer, 1997
- USE OF THE WEI-LIN-WEISSFELD METHOD FOR THE ANALYSIS OF A RECURRING AND A TERMINATING EVENTStatistics in Medicine, 1997
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaThe New England Journal of Medicine, 1996
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982